Orthofix International N.V. continues its transformation with the announcement on March 24, 2014, that Ron Matricaria is the company’s new chairman of the board.
Matricaria Assumes Orthofix Chair
1 min read Premium comments
Secondary
He replaces Kathy Regan, who has served as Interim Chair since January. Ms. Regan will continue to serve as an independent director for the company and Chair of the Nominating and Governance Committee.
Regan said she sees this “significant event” as an example of the efforts being made to position the company for long-term stability and growth.
Matricaria, according to the company announcement, has more than 35 years of medical device and pharmaceutical experience at St. Jude Medical, Inc. and Eli Lilly and Company. He is also currently chairman of the Board at Volcano Corporation Inc., a member of the board at Phoenix Children’s Hospital and, most recently, served as a director at Life Technologies Corporation.
Additionally, Matricaria has served on the board of a number of public and private companies including Home Depot Inc., Diametric Medical Inc., Ceridian Inc., Centocor Inc., Haemonetics Inc., Kinetic Concepts, Inc., Hospira Inc., Cyberonics Inc., Vistacare Inc., Advanced Medical Technology Association (AdvaMed), the Pharmaceutical Manufacturers Association International Section, the American Diabetes Association, the American Foundation for Pharmaceutical Education, the National Foundation for Infectious Diseases, the National Retiree Volunteer Center and the Indiana Repertory Theatre as well as a trustee on the board of the Massachusetts College of Pharmacy and Allied Health Science. He also chaired the BioMedical Engineering Institute campaign, which raised an operating endowment for the Institute at the University of Minnesota. He remains a Trustee emeritus of the University of Minnesota Foundation.
Matricaria said Orthofix has been through a lot over the last few years. President and CEO Brad Mason noted that he now has an active and experienced board. Added Mason, “I am confident we can build the foundation to maximize the value of our technologies, core competencies, and relationships.”
In addition to announcing the appointment of Matricaria, the company also completed the filing of its previously announced financial statement restatement. See accompanying news item for full details.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.